The country's fifth-largest drugmaker by domestic sales is expecting to get SEBI approval to its IPO by December and is targeting a valuation of Rs 15,000 crore.
first published: May 20, 2015 06:22 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty extends gain to the second straight day but sees another weekly loss | Closing Bell
Live: Can Nifty extend gains and reclaim 26,000? | Opening Bell
FSS Simply Payments 2025 | AI in Payments: Building a Governance-First Future.
Live: Nifty reclaims 25,900, snaps 3-day losing streak; rupee falls to fresh low | Closing Bell
